Daily Cosmetic Research Analysis
Three impactful studies span prevention, aesthetics, and dermatologic therapy. A BMJ Open Ophthalmology study proposes a contact lens Sun Protection Factor (CL-SPF) with laboratory, ray-tracing, and cell assays, enabling clearer UV-protection communication. An international Delphi consensus outlines first global guidance for managing aesthetic needs in medication-driven weight loss. A randomized trial supports facial/neck atopic dermatitis control with ruxolitinib cream using decentralized, phot
Summary
Three impactful studies span prevention, aesthetics, and dermatologic therapy. A BMJ Open Ophthalmology study proposes a contact lens Sun Protection Factor (CL-SPF) with laboratory, ray-tracing, and cell assays, enabling clearer UV-protection communication. An international Delphi consensus outlines first global guidance for managing aesthetic needs in medication-driven weight loss. A randomized trial supports facial/neck atopic dermatitis control with ruxolitinib cream using decentralized, photo-based assessments.
Research Themes
- UV protection metrics and ocular health communication
- Aesthetic management during medication-driven weight loss (GLP-1 era)
- Topical JAK inhibition for facial/neck atopic dermatitis
Selected Articles
1. Development of a Sun Protection Factor for contact lenses (CL-SPF).
Using standardized SPF methods, spectrophotometry, ray tracing, and in vitro cell assays, the authors propose a contact lens SPF (CL-SPF) that maps lens UV-block performance to familiar SPF categories. Class 1 UV-blocking lenses reached CL-SPF ~60–66 (SPF 50+ equivalent), while non-blocking lenses offered CL-SPF ~1–2. Geometry-dependent sunglass gaps and higher conjunctival UV susceptibility underscore that lenses protect mainly the cornea.
Impact: Introduces a consumer-friendly, cross-disciplinary metric with methodological triangulation that can standardize UV-protection labeling for contact lenses and inform counseling alongside sunglasses use.
Clinical Implications: Eye care professionals can use CL-SPF to communicate UV protection, recommend Class 1 UV-blocking lenses for high-risk patients, and emphasize that contact lenses do not protect exposed conjunctiva/sclera—necessitating sunglasses and hats.
Key Findings
- Measured UV transmission of 15 contact lenses and 3 spectacle materials; derived CL-SPF using standard in vitro SPF methodology.
- Non-UV-blocking lenses: CL-SPF 1.0–2.0; Class 2 blockers: 12.3–24.8 (≈SPF15); Class 1 blockers: 59.6–66.2 (≈SPF50+).
- Ray tracing showed sunglasses’ ocular protection varies with solar angle and head orientation; average 76%–89% light reduction depending on tint.
- In vitro assays indicate ocular surface cell damage profile similar to skin, with conjunctival cells more UV-susceptible.
Methodological Strengths
- Triangulation of spectrophotometry, standardized SPF modeling, ray tracing, and cell assays.
- Direct mapping to widely understood SPF categories enhances translational relevance.
Limitations
- In vitro and modeling study without clinical UV exposure outcomes.
- Limited product set and lab conditions may not capture real-world wear environments.
Future Directions: Prospective studies linking CL-SPF categories to clinical photoprotection outcomes and development of standardized labeling across manufacturers; evaluation of combined strategies (CLs + sunglasses/hats).
OBJECTIVE: Sun Protection Factor (SPF) of sunscreen products is well recognised by consumers. This study explored how SPF could be applied to ultraviolet radiation (UV) protection from contact lenses (CL-SPF). METHODS AND ANALYSIS: UV transmission through 15 commercially available contact lenses and three spectacle lens materials was measured with a deuterium light source and spectrophotometer. CL-SPF values were calculated using the standard in vitro method used to test and label skin products. Ray tracing was applied to two sunglass designs to assess the effect of solar angle and head orientation on light reaching the ocular surface. Cellular damage profile of human corneal and conjunctival cells across the UV range was assessed in vitro to inform an SPF equivalent for CLs. RESULTS: CLs tested fell into three categories: CL-SPF with no UV blocker=1.0-2.0 (equivalent to using no sunscreen); CL-SPF with Class 2 UV blocker=12.3-24.8 (equivalent to SPF15); and CL-SPF with Class 1 UV blocker=59.6-66.2 (equivalent to SPF 50+). Despite the UV-blocking characteristics of sunglasses, ocular surface protection can be substantially reduced at certain solar angle and head orientation combinations; on average, 76%-89% of light was prevented from reaching the ocular surface depending on the intensity of the tint (80%-20% transmission). The data also suggest that cell damage and death of ocular surface cells has a similar profile to that of the skin, but conjunctival cells are more susceptible to UV damage. CONCLUSION: CL-SPF is a viable metric to communicate the protection from the absorption/transmission of UV radiation that CLs offers wearers. However, a contact lens will only project the area of the ocular surface it covers, which is limited to mainly the cornea and internal eye tissues with soft CLs.
2. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study.
Through a three-round international Delphi process grounded in interviews, market research, and a literature review, experts defined medication-driven weight loss (mdWL), identified affected facial tissue layers (skin; superficial/deep fat), and recommended 3D volumetric analysis plus PROMs for assessment. The consensus outlines sequencing and timing of non-surgical treatments and highlights patient/physician concerns to guide aesthetic care in the GLP-1 era.
Impact: This is the first global consensus addressing the rapidly expanding mdWL population, providing practical, multidisciplinary algorithms likely to shape aesthetic assessment and treatment sequencing.
Clinical Implications: Adopt 3D volumetric analysis and PROMs for mdWL assessment; prioritize skin and fat pad changes; plan treatment sequencing to avoid an appearance of weight regain while maintaining natural, healthy outcomes.
Key Findings
- mdWL best defined by the percentage of BMI lost within ≤6 months.
- 3D volumetric analysis is recommended for quantitative assessment; photo-numeric scales and PROMs for qualitative assessment.
- mdWL primarily affects skin and both superficial and deep facial fat pads.
- Consensus details selection and timing of non-surgical treatments across the mdWL journey and addresses patient/physician concerns.
Methodological Strengths
- International, multidisciplinary panel with three-round Delphi methodology.
- Triangulated preparatory work (patient interviews, market research, systematic literature review).
Limitations
- Consensus-based guidance lacks randomized comparative evidence.
- Panel size and voting thresholds not specified in the abstract; external validity may vary by practice setting.
Future Directions: Prospective validation of proposed assessment tools and treatment sequencing, and head-to-head studies of aesthetic interventions stratified by mdWL trajectory and tissue changes.
BACKGROUND: To handle the increasing influx of prescription medication-driven weight loss (mdWL) patients in aesthetic practices, clinicians must be aligned on identifying discerning factors and strategies for managing this unique patient population. OBJECTIVES: (1) Define the mdWL patient; (2) describe the mdWL patient's aesthetic expectations; (3) determine the most relevant methods of assessing mdWL patients in clinical practice; (4) determine the effects of mdWL on specific facial tissue layers; (5) identify important treatment considerations for the mdWL patient; and (6) identify the temporal sequencing of non-surgical options in the mdWL patient. METHODS: Preparatory research included patient interviews, market research, and a systematic literature review. Following this, an international, multidisciplinary three-round Delphi study was conducted to collect information on practice setting, physician and patient demographics, and previous experience, and for panelists to vote on consensus statements regarding managing mdWL patients in aesthetics. RESULTS: mdWL is best defined by the percent of BMI lost within ≤ 6 months. Three-dimensional volumetric analysis is an effective quantitative assessment, while photo-numeric scales and patient-reported outcome measures are relevant qualitative measures. Tissue layers most affected by mdWL include the skin and superficial and deep fat pads. A major concern for aesthetic mdWL patients seeking aesthetic treatments is the fear of appearing to have gained weight following treatments, while for physicians it is ensuring their mdWL patients look healthy and natural. The key selection and critical timing of aesthetic treatments throughout the mdWL journey are described. CONCLUSIONS: The first global consensus-based guidelines for understanding and managing the aesthetic needs of mdWL patients are presented.
3. Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial.
In a decentralized, double-blind phase 2 trial (n=77), twice-daily 1.5% ruxolitinib cream achieved higher head/neck EASI-75 responses at Week 4 than vehicle (37.0% vs 17.4%) using blinded photographic assessments; treatment was well tolerated. After Week 4, all patients used as-needed ruxolitinib through Week 8.
Impact: Provides controlled evidence specific to the cosmetically sensitive face/neck areas using decentralized, blinded photographic assessments, supporting topical JAK inhibition in regions where tolerability and safety drive prescribing.
Clinical Implications: Ruxolitinib cream is a reasonable option for facial/neck AD where steroid-sparing and tolerability are priorities; decentralized photo-based monitoring could facilitate access and adherence.
Key Findings
- Randomized 2:1, double-blind, decentralized phase 2 trial with 77 patients (44.2% Black), baseline head/neck EASI 1.2.
- Week-4 head/neck EASI-75 responses favored ruxolitinib cream over vehicle (37.0% vs 17.4%) using blinded central photographic assessment.
- Ruxolitinib cream was well tolerated; all patients transitioned to as-needed use through Week 8.
Methodological Strengths
- Double-blind randomized design with central blinded photographic assessment.
- Decentralized trial conduct increases generalizability and patient access.
Limitations
- Short primary treatment window (4 weeks) and small sample size limit power and durability assessment.
- Low baseline head/neck EASI may constrain generalizability to more severe disease.
Future Directions: Larger, longer trials comparing ruxolitinib cream to active comparators on face/neck, with safety endpoints relevant to sensitive skin and skin of color, and real-world decentralized monitoring.
PURPOSE: Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421). MATERIALS AND METHODS: Patients aged 12-70 years with AD (Investigator's Global Assessment [IGA] score 2/3, ≤20% affected body surface area [face/neck, ≥0.5%]) were randomized 2:1 to twice-daily 1.5% ruxolitinib cream or vehicle for 4 weeks; thereafter, all patients applied as-needed ruxolitinib cream for 4 additional weeks. The primary endpoint was ≥75% improvement in head/neck Eczema Area and Severity Index (EASI-75) at Week 4 assessed by blinded central reader using photographs. RESULTS: Among 77 randomized patients (median [range] age, 38.0 [17-66] y), 44.2% were Black. The mean (SD) baseline head/neck EASI was 1.2 (0.7). More patients who applied ruxolitinib cream vs vehicle achieved head/neck EASI-75 at Week 4 (37.0% vs 17.4%; CONCLUSIONS: Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.